z-logo
open-access-imgOpen Access
Consensus statement on management of chronic heart failure in India
Author(s) -
Sandeep Seth,
Balram Bhargava,
SK Maulik,
Theresa A. McDonagh,
Anitá Saxena,
Balram Airan,
Calambur Narasimhan,
Milind Padmakar Hote,
Neeraj Parakh,
Ajay Bahl,
Sivasubramanian Ramakrishnan,
Vivek Chaturvedi,
Ranjit Kumar Nath,
Praloy Chakroborthy
Publication year - 2015
Publication title -
journal of the practice of cardiovascular sciences
Language(s) - English
Resource type - Journals
eISSN - 2454-2830
pISSN - 2395-5414
DOI - 10.4103/2395-5414.166340
Subject(s) - heart failure , medicine , digoxin , spironolactone , nebivolol , bisoprolol , carvedilol , cardiology , metoprolol , eplerenone , aldosterone , furosemide , mineralocorticoid receptor , intensive care medicine , blood pressure
Summary of the Consensus Statement: This statement has been prepared keeping Indian heart failure patients in mind. Optimal management of CHF improves quality of life, reduces hospitalization rates and prolongs survival for people with this condition. Echocardiography is the single most useful test in the evaluation of heart failure, and is necessary to confirm the diagnosis. Plasma B-natriuretic peptide (BNP) measurements may be useful in excluding CHF but not mandatory in India. Educate people with CHF about lifestyle changes (e.g., increase physical activity levels, reduce salt intake and manage weight). Educate people with CHF about CHF symptoms and how to manage fluid load. Avoid prescribing drugs that exacerbate CHF. Prescribe angiotensin-converting enzyme inhibitors (ACEI) at effective doses for people with all grades of systolic heart failure, and titrate to the highest recommended dose tolerated. Angiotensin II receptor antagonists (ARA) may be used as alternatives in people who cannot tolerate ACEIs. Mineralocorticoid receptor antagonists (MRAs) should also be used. For people with stabilised systolic heart failure, prescribe beta-blockers that have been shown to improve outcome in heart failure (e.g., bisoprolol, carvedilol, extended release metoprolol or nebivolol). Titrate to the highest recommended dose tolerated. Prescribe diuretics, digoxin and nitrates for people already using ACEIs and beta-blockers to manage symptoms as indicated. For people who have systolic heart failure (New York Heart Association (NYHA) Class II-IV) despite appropriate doses of ACEIs and diuretics, consider prescribing spironolactone. Eplerenone can be considered in certain setting especially post myocardial infarction though it is more expensive. Consider direct sinus node inhibition with ivabradine for people with CHF who have impaired systolic function, have had a recent heart failure hospitalisation and are in sinus rhythm with a heart rate >70 bpm despite beta blockers or where beta blockers are contraindicated Check for, and treat, iron deficiency in people with CHF to improve their symptoms, exercise tolerance and quality of life Consider assessing people with CHF for biventricular pacemakers and implantable defibrillators. Patients with end stage heart failure have an option for heart transplant and ventricular assist devices which is now available in select centers

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here